Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23362891 | 0.87 | PTGS2 (0.43) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL18329542 | 0.85 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1671329 | 0.83 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8488636 | 0.82 | ABL1 (0.45) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL1495245 | 0.82 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3205636 | 0.81 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31284126 | 0.81 | TSHR (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29570135 | 0.81 | TSHR (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1164172 | 0.79 | ALDH1A1 (0.48) | GAALMNAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3829091 | 0.79 | DPP4 (0.50) | PTGS2GAAALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100534-A1 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | UBE CORPORATION (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20230100534-A1 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | UBE CORPORATION (JP) | 2023-03-30 | — | — | US | disclosed |
| US-11407831-B2 | Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent | UBE INDUSTRIES, LTD. (JP) | 2022-08-09 | — | — | US | disclosed |
| CN-107735401-B | Substituted dihydropyrrolopyrazole derivatives | 宇部兴产株式会社 | 2021-08-31 | — | — | CN | disclosed |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| EP-3705124-A1 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | Ube Industries, Ltd. (JP) | 2020-09-09 | — | — | EP | disclosed |
| EP-3705124-A1 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | Ube Industries, Ltd. (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-20200262924-A1 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | UBE INDUSTRIES, LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
| US-20200262924-A1 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | UBE INDUSTRIES, LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | disclosed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016204153-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | 宇部興産株式会社 | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | PTGS2 2472/4885CA12 3634/4885CA1 3470/4885 |
| US-20230100534-A1 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | IL2, CYP2D6, IL2RA | PTGS2 2847/4885CA12 1428/4885CA1 2937/4885 |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | PTGS2 2472/4885CA12 3634/4885CA1 3470/4885 |
| US-20200262924-A1 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | IL2, CYP2D6, CYP3A43 | PTGS2 3158/4885CA12 1789/4885CA1 3394/4885 |
| US-11407831-B2 | Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent | IL2, CYP2D6, CYP3A43 | PTGS2 3158/4885CA12 1789/4885CA1 3394/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | PTGS2 2472/4885CA12 3634/4885CA1 3470/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | PTGS2 2472/4885CA12 3634/4885CA1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.